B of A Securities Upgrades Novavax to Neutral, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Alec Stranahan upgrades Novavax (NVAX) from Underperform to Neutral and raises the price target from $4 to $12.
May 10, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax was upgraded by B of A Securities from Underperform to Neutral with a price target increase from $4 to $12, indicating a more favorable outlook on the stock.
The upgrade from Underperform to Neutral by a major analyst and the significant increase in price target suggests a positive reassessment of Novavax's prospects. This is likely to be viewed positively by the market, potentially leading to a short-term increase in NVAX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100